Researchers at the New York Blood Center have made a breakthrough in understanding the body’s autoimmune response to sickle ...

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.

A research team has revealed that cadmium, a toxic heavy metal, increases the synthesis of hyaluronan in vascular endothelial ...

Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...

Molecular communications in the bloodstream is a promising area of research, since the bloodstream has the ability to ...